IPO registrations (S-1, F-1) · Registrants
NextCure, Inc.
- SEC CIK
- 1661059 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2019-04-12, last 2019-11-14; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2019-05-09; declared effective 2019-05-08
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 2850 QUARRY LAKE DRIVE, SUITE 280, Baltimore, MD 21209
- EIN
- 47-5231247
- Ticker
- NXTC (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- NextCure, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2019-05-03)
- Final price
- $15.00 per share, within the range (424B4 filed 2019-05-09, an initial public offering)
- Shares sold
- 5,000,000
- Gross proceeds
- $75,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol NXTC
- Lead underwriters
- Morgan Stanley (2,075,000 shares)
- Syndicate
- BofA Securities; Piper Sandler; Merrill Lynch (1,925,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: NEXTCURE, INC. EXACT (EIN (EXACT))
- Form D issuer: NextCure, Inc. EXACT (CIK (EXACT))
- SEC filer: NextCure, Inc. EXACT (CIK (EXACT))
- Person page: Elaine V Jones Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: John G Houston Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 12
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-04-12 | S-1 | S-1 (registration) | NextCure, Inc. | 0001047469-19-002203 ↗ |
| 2019-04-29 | S-1/A | S-1/A (amendment) | NextCure, Inc. | 0001047469-19-002652 ↗ |
| 2019-05-03 | S-1/A | S-1/A (amendment) | NextCure, Inc. | 0001047469-19-002857 ↗ |
| 2019-05-08 | S-1/A | S-1/A (amendment) | NextCure, Inc. | 0001047469-19-002935 ↗ |
| 2019-05-08 | EFFECT | EFFECT (declared effective) | NextCure, Inc. | 9999999995-19-001046 ↗ |
| 2019-05-09 | 424B4 | 424B4 (final prospectus) | NextCure, Inc. | 0001047469-19-002988 ↗ |
| 2019-11-12 | S-1 | S-1 (registration) | NextCure, Inc. | 0001047469-19-006237 ↗ |
| 2019-11-14 | S-1/A | S-1/A (amendment) | NextCure, Inc. | 0001047469-19-006303 ↗ |
| 2019-11-14 | S-1MEF | S-1MEF (added securities) | NextCure, Inc. | 0001104659-19-064433 ↗ |
| 2019-11-14 | EFFECT | EFFECT (declared effective) | NextCure, Inc. | 9999999995-19-002590 ↗ |
| 2019-11-18 | 424B4 | 424B4 (final prospectus) | NextCure, Inc. | 0001047469-19-006335 ↗ |
| 2021-03-12 | EFFECT | EFFECT (declared effective) | NextCure, Inc. | 9999999995-21-000928 ↗ |
Prospectus pages read 3
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-05-03 | S-1/A | registration statement | $14.00–$16.00 | 5,000,000 | - | Nasdaq NXTC | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2019-05-08 | S-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2019-05-09 | 424B4 | final prospectus | $15.00 | 5,000,000 | $75,000,000 | Nasdaq NXTC | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | TenPercentOwner | 2 | 2019 | ||
| Bingham James B. | Officer | Chief Development Officer | 2 | 2019–2020 | |
| Canaan Partners X LLC | TenPercentOwner | 2 | 2019 | ||
| CANAAN X L.P. | TenPercentOwner | 2 | 2019 | ||
| Cobourn Steven P. | Officer | Chief Financial Officer | 9 | 2019–2026 | |
| HEALY JAMES | TenPercentOwner | 3 | 2019 | ||
| Heller Kevin N. | Officer | Chief Medical Officer | 3 | 2019–2020 | |
| Jones Elaine V | Director | 9 | 2019–2026 | person page Fuzzy | |
| KABAKOFF DAVID S | Director | 9 | 2019–2026 | ||
| Khuong Chau Quang | Director | 7 | 2019–2023 | ||
| Langermann Sol | Officer | Chief Scientific Officer | 8 | 2019–2025 | |
| Li Judith | Director | 3 | 2019–2020 | ||
| Liu Linda | Officer | SVP, Research | 5 | 2019–2022 | |
| Mayer Timothy | Officer | Chief Operating Officer; SVP, Corporate Development | 9 | 2019–2026 | |
| Mehra Anand | TenPercentOwner | 3 | 2019 | ||
| Morrison Briggs | Director | 3 | 2019–2020 | ||
| ORBIMED ADVISORS LLC | Director,TenPercentOwner | 2 | 2019 | ||
| OrbiMed Capital GP VI LLC | Director,TenPercentOwner | 2 | 2019 | ||
| POWELL MICHAEL | TenPercentOwner | 3 | 2019 | ||
| Quan Venture Fund II, L.P. | TenPercentOwner | 1 | 2019 | ||
| Richman Michael | Director,Officer; Director,Officer,TenPercentOwner | President & CEO | 9 | 2019–2026 | |
| SHANNON TIMOTHY M | Director | 3 | 2019 | ||
| Sofinnova Management IX, L.L.C. | TenPercentOwner | 3 | 2019 | ||
| Sofinnova Venture Partners IX, L.P. | TenPercentOwner | 3 | 2019 | ||
| Webster Stephen W | Director | 9 | 2019–2026 | ||
| Xu Stella | Director; Director,TenPercentOwner | 5 | 2019–2021 | ||
| Nicholson Garry A | Director | 5 | 2020–2023 | ||
| Houston John G | Director | 8 | 2020–2026 | person page Fuzzy | |
| Myint Han | Officer | Chief Medical Officer | 6 | 2021–2024 | |
| Kundu Sourav | Officer | Sr VP, Dev. & Mfg. | 8 | 2021–2026 | |
| Borgman Anne Elizabeth | Director | 7 | 2021–2026 | ||
| Feigal Ellen | Director | 7 | 2021–2026 | ||
| Shaw Kevin G. | Officer | Sr VP, General Counsel; Sr VP, Legal Affairs | 6 | 2023–2026 | |
| Guha Udayan | Officer | Chief Medical Officer | 2 | 2025–2026 | |
| Simcere Zaiming, Inc. | Other; TenPercentOwner | 3 | 2025–2026 | ||
| Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Other; TenPercentOwner | 2 | 2025–2026 | ||
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | Other; TenPercentOwner | 2 | 2025–2026 | ||
| Ren Jinsheng | Other; TenPercentOwner | 2 | 2025–2026 | ||
| Simcere Pharmaceutical Group Ltd | Other; TenPercentOwner | 2 | 2025–2026 | ||
| Tang Renhong | Other; TenPercentOwner | 2 | 2025–2026 | ||
| ADAR1 Capital Management, LLC | TenPercentOwner | 3 | 2026 | ||
| Schneeberger Daniel | TenPercentOwner | 3 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-12-10 | NextCure, Inc. | Biotechnology | $21,500,000 | $21,500,000 | 12 | 1 |
| 2018-11-19 | NextCure, Inc. | Biotechnology | $93,432,873 | $93,432,873 | 22 | 1 |
| 2016-01-11 | NextCure, Inc. | Biotechnology | $67,000,000 | $15,000,000 | 7 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form 5500 plan sponsor | NEXTCURE, INC. | EIN (EXACT) | ||
| Form D issuer | NextCure, Inc. | Form D private offerings | CIK (EXACT) | |
| Person page | Elaine V Jones | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | John G Houston | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| SEC filer | NextCure, Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.